News Feed
Clinical, regulatory, and market intelligence across the GLP-1 and peptide therapeutics space.
FDA updates supply chain guidance for GLP-1 compounding pharmacies
New restrictions on wholesale bulk peptide ingredients aim to stabilize market quality standards and clarify the boundary between approved and compounded products.
Dr. Elias Vance · 5 min
Tirzepatide long-term cardiovascular outcomes show 15% risk reduction
SURMOUNT-CV trial results presented at a metabolic health summit exceeded initial analyst projections for major adverse cardiovascular event reduction.
Dr. Priya Nair · 7 min
Phase II data for oral GLP-1 alternatives shows promising bioavailability
A next-generation oral peptide formulation achieved bioavailability approaching that of injectable analogs without SNAC absorption enhancers.
Dr. Aris Varma · 6 min
Tirzepatide production scaling via new European bioreactor facilities
Three new bioreactors scheduled to come online in Ireland by Q1 aim to close the gap between soaring demand and finite peptide synthesis capacity.
Elena Ricci · 4 min
Retatrutide Phase III program enrolls first patients in TRIUMPH cohort
The triple-agonist program advances into pivotal trials, setting up a potential head-to-head with dual agonists on the obesity standard of care.
Dr. Priya Nair · 5 min
Sector M&A volume climbs to $42.8B YTD on peptide dealmaking
Licensing activity around next-generation multi-receptor agonists drove a record quarter for GLP-1 and peptide therapeutic transactions.
Marcus Holloway · 6 min
Survodutide MASH readout signals class-level hepatology potential
Dual GLP-1/glucagon agonism produced meaningful fibrosis improvement in a Phase II MASH population, broadening the therapeutic scope of the class.
Dr. Elias Vance · 5 min